Alzheimer’s Disease (AD)

Spinogenix’s Alzheimer’s drug touts disease-modifying potential in Phase IIa study

Early positive signals of cognitive outcomes in mild to moderate Alzheimer patients treated with the synaptic regenerative small molecule, SPG302 – AAIC 2025 Poster

Inside A Bold New Approach To Alzheimer’s

Enhancing Neurodegenerative Care: Dialogue Exchange with Stella Sarraf of Spinogenix

To Reverse Aging’s Clock, Adjust the Cell’s Machinery

Early Clinical Development of Synapse-Focused Agent SPG302 for Alzheimer Disease

Sydney Alzheimer’s Patients Will Be The First to Trial a New Drug

Hope Pill Will Turn Tables on Dementia

By Lisa Wachsmuth If there was a magic pill to slow the progression of Phil Hazel’s Alzheimer’s disease and allow him to forever retain the happy memories he’s made with his wife Jan, he’d happily swallow it. The Sydney retiree may one day get that chance, with a world-first trial to begin in ­Sydney this…

Synapse-regenerating drug could reverse decline in Alzheimer’s